- Agenus Inc. (AGEN, Financial) presents promising data from the NEOASIS study at AACR Annual Meeting.
- The study shows significant efficacy of BOT/BAL therapy in treating various solid tumors.
- No dose-limiting toxicities were observed, and all patients proceeded to surgery on schedule.
Agenus Inc. (AGEN), a leader in immuno-oncology, recently showcased significant findings from the NEOASIS study at the American Association for Cancer Research (AACR) Annual Meeting in Chicago. The study assessed the efficacy of botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for multiple solid tumors, marking the third clinical evaluation of these agents.
The NEOASIS Phase 2 trial involved patients with non-metastatic solid tumors, categorized into two cohorts: mismatch repair–deficient (dMMR/MSI-H) and mismatch repair–proficient (pMMR/MSS). Results highlighted a 90% pathological response rate for the dMMR/MSI-H cohort and an 80% response rate for the pMMR/MSS cohort. Furthermore, 63% of patients in the triple-negative breast cancer subgroup achieved a major pathological response (MPR).
Importantly, the study observed no dose-limiting toxicities, ensuring all participants proceeded to surgery without delay. Dr. Steven O’Day, Chief Medical Officer at Agenus, emphasized the substantial potential of BOT/BAL in early-stage cancer treatments, especially for tumors resistant to traditional immunotherapies.
For additional information on the NEOASIS study and other clinical trials involving botensilimab and balstilimab, interested parties can visit the company’s dedicated resources.
